|
JPS6045180B2
(ja)
*
|
1977-05-17 |
1985-10-08 |
第一製薬株式会社 |
２−アミノテトラリン誘導体
|
|
FR2691145A1
(fr)
|
1992-05-18 |
1993-11-19 |
Inst Nat Sante Rech Med |
Nouveaux dérivés de la dihydroxybenzylamine, leur préparation et les compositions pharmaceutiques qui les contiennent.
|
|
US5807897A
(en)
*
|
1996-03-01 |
1998-09-15 |
Zeneca Limited |
Aminotetralin derivative and compositions and method of use thereof
|
|
US6225352B1
(en)
|
1996-08-14 |
2001-05-01 |
Warner-Lambert Company |
Low molecular weight dendritic compounds as pharmaceutical agents
|
|
US6201025B1
(en)
|
1998-10-07 |
2001-03-13 |
Ortho-Mcneil Pharmaceutical, Inc. |
N-aralkylaminotetralins as ligands for the neuropeptide Y Y5 receptor
|
|
WO2001009120A1
(en)
|
1999-07-28 |
2001-02-08 |
Ortho-Mcneil Pharmaceutical, Inc. |
Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
|
|
DE10007948A1
(de)
|
2000-02-22 |
2001-09-06 |
Wella Ag |
Mittel zur Färbung von Fasern
|
|
FR2809396B1
(fr)
|
2000-05-24 |
2005-10-14 |
Centre Nat Rech Scient |
Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
|
|
DK1859798T3
(en)
|
2001-03-29 |
2016-03-21 |
Lilly Co Eli |
N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor
|
|
US20050152858A1
(en)
|
2003-07-11 |
2005-07-14 |
Isp Investments Inc. |
Solubilizing agents for active or functional organic compounds
|
|
US20070196395A1
(en)
|
2003-12-12 |
2007-08-23 |
Mackerell Alexander |
Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
|
|
US7598255B2
(en)
*
|
2005-08-04 |
2009-10-06 |
Janssen Pharmaceutica Nv |
Pyrimidine compounds as serotonin receptor modulators
|
|
US9101613B2
(en)
|
2006-02-15 |
2015-08-11 |
Neurim Pharmaceuticals (1991) Ltd. |
Methods for treating neurological disease
|
|
BRPI0713736A2
(pt)
*
|
2006-06-20 |
2014-11-18 |
Hoffmann La Roche |
Derivados de tetralina e indano e emprego destes
|
|
US20080248511A1
(en)
|
2007-03-26 |
2008-10-09 |
Promega Corporation |
Methods to quench light from optical reactions
|
|
US20080318957A1
(en)
|
2007-05-11 |
2008-12-25 |
Mpex Pharmaceuticals, Inc. |
Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof
|
|
JP5773877B2
(ja)
|
2008-10-22 |
2015-09-02 |
アキュセラ インコーポレイテッド |
眼の疾患及び障害を治療する化合物
|
|
WO2011047165A1
(en)
|
2009-10-16 |
2011-04-21 |
Southern Illinois University Edwardsville |
Methods for treating memory impairment
|
|
EP2418196A1
(en)
|
2010-07-29 |
2012-02-15 |
IMTM GmbH |
Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors
|
|
GB201409516D0
(en)
|
2014-05-29 |
2014-07-16 |
Randox Lab Ltd |
Immunoassay for compounds of the NBOMe family
|
|
US10454900B2
(en)
|
2015-09-25 |
2019-10-22 |
Mcafee, Llc |
Remote authentication and passwordless password reset
|
|
CN110177581B
(zh)
|
2016-11-16 |
2023-01-03 |
通用医疗公司 |
髓过氧化物酶显像剂
|
|
WO2019084338A1
(en)
|
2017-10-25 |
2019-05-02 |
University Of South Florida |
DRUG-INDUCED ACTIVATION OF THE REELIN SIGNALING SYSTEM
|
|
EP4417596B1
(en)
|
2017-11-06 |
2026-04-29 |
Acelot, Inc. |
Small molecule drugs and related methods for treatment of diseases related to a-beta-42 oligomer formation
|
|
WO2019099402A1
(en)
|
2017-11-14 |
2019-05-23 |
Rutgers, The State University Of New Jersey |
Therapeutic compounds and methods to treat infection
|
|
BR112020011189A2
(pt)
|
2017-12-05 |
2020-11-17 |
Sunovion Pharmaceuticals Inc. |
misturas não racêmicas e usos das mesmas
|
|
AU2019324952B2
(en)
|
2018-08-22 |
2024-10-24 |
University Of Technology Sydney |
NBOMe test
|
|
JP7731868B2
(ja)
|
2019-08-02 |
2025-09-01 |
エースロット，インコーポレイテッド |
ＴＤＰ－４３、α－シヌクレイン、ハンチンチンタンパク質及びタウタンパク質のオリゴマー形成に関連する疾患を治療するための小分子薬物、並びに関連する方法
|
|
AU2020386445B2
(en)
|
2019-11-19 |
2025-12-18 |
Paul Edward Stamets |
Tryptamine compositions for enhancing neurite outgrowth
|
|
US12534425B2
(en)
|
2020-06-29 |
2026-01-27 |
Gilgamesh Pharmaceuticals, Inc. |
Phenalkylamines and methods of treating mood disorders
|
|
CN119285527A
(zh)
|
2020-06-30 |
2025-01-10 |
瑞安神经科学公司 |
色胺前药
|
|
JP2024512796A
(ja)
|
2021-04-01 |
2024-03-19 |
テラン バイオサイエンシーズ インク． |
サイケデリック薬およびセロトニン受容体調節因子に関する方法と組成物
|
|
EP4337220A4
(en)
|
2021-05-11 |
2025-07-02 |
Saint Josephs Univ |
SELECTIVE, PARTIAL, AND POLARIZED 5-HT2A AGONISTS WITH UTILITY IN VARIOUS DISORDERS
|
|
WO2022261263A1
(en)
|
2021-06-08 |
2022-12-15 |
Gilgamesh Pharmaceuticals, Inc. |
Methods of treating neuropsychiatric disorders
|
|
MX2023014630A
(es)
|
2021-06-08 |
2024-01-30 |
Atai Therapeutics Inc |
Activadores de dimetoxifenilalquilamina de receptores de serotonina.
|
|
CA3239571A1
(en)
|
2021-12-15 |
2023-06-22 |
Noel Aaron Powell |
Fused pyrrolidine psychoplastogens and uses thereof
|
|
EP4457203A4
(en)
|
2021-12-27 |
2025-12-17 |
Atai Therapeutics Inc |
AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS
|
|
WO2024124056A1
(en)
|
2022-12-07 |
2024-06-13 |
Entheogenix Biosciences, Inc. |
Novel sulfoximine activators of serotonin receptors
|
|
EP4637736A1
(en)
|
2022-12-22 |
2025-10-29 |
ATAI Therapeutics, Inc. |
Prodrugs of dimethoxyphenylalkylamine activators of serotonin receptors
|
|
EP4637735A1
(en)
|
2022-12-22 |
2025-10-29 |
ATAI Therapeutics, Inc. |
Dimethoxyphenyl heteroaromatic alkylamine activators of serotonin receptors
|
|
EP4680236A2
(en)
|
2023-03-16 |
2026-01-21 |
ATAI Therapeutics, Inc. |
3-alkylamine indole activators of serotonin receptors
|
|
US12343319B2
(en)
|
2023-05-01 |
2025-07-01 |
Atai Therapeutics, Inc. |
Compositions and methods for treatment of diseases and disorders
|